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S U M M A R Y
Background: Namibia experienced a large measles outbreak starting in 2009, with 38% of reported cases
in adults, including women of reproductive age. Population immunity was assessed among pregnant
women to determine whether immunization activities were needed in adults to achieve measles
elimination in Namibia.
Methods: A total of 1708 and 2040 specimens sampled from Namibian pregnant women aged 15–44
years who were included in the 2008 and 2010 National HIV Sentinel Survey, respectively, were tested
for measles immunoglobulin G antibody. The proportion of women seropositive overall and by 5-year
age strata was determined, and factors associated with seropositivity were analyzed by logistic
regression, including age, facility type, gravidity, HIV status, and urban/rural setting. Seropositivity in
2008 versus 2010 was compared.
Results: In both analysis years, measles seropositivity was lower in 15–19-year-olds (77%) and 20–24-
year-olds (85–87%) and higher in 25–44-year-olds (90–94%) (2008, p < 0.001; 2010, p < 0.001). Overall
measles seropositivity did not differ between 2008 (87%) and 2010 (87%) (p = 0.7). HIV status did not
affect seropositivity.
Conclusions: Late in a large measles outbreak, 13% of pregnant women in Namibia, and almost one in four
15–19-year-old pregnant women, remained susceptible to measles. In Namibia, immunization
campaigns with measles-containing vaccine should be considered for adults.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Globally, the number of reported measles cases decreased by
73% from 2000 to 2014.1 In the World Health Organization (WHO)
African Region, estimated measles deaths decreased during this
period by 86%; nonetheless, outbreaks continued to occur in thisDOI of original article: http://dx.doi.org/10.1016/j.ijid.2016.05.009
§ The ﬁndings and conclusions in this report are those of the authors and do not
necessarily represent the ofﬁcial position of the Centers for Disease Control and
Prevention.
* Corresponding author. Tel.: +1 404 639 8241; fax: +1 404 417 0962.
E-mail address: iyk8@cdc.gov (C.V. Cardemil).
http://dx.doi.org/10.1016/j.ijid.2016.05.020
1201-9712/Published by Elsevier Ltd on behalf of International Society for Infectious
creativecommons.org/licenses/by-nc-nd/4.0/).region and accounted for 73 914 cases and an estimated
48 000 deaths in 2014, representing 42% of the global measles
mortality burden.1
In the pre-vaccine era, measles was primarily an illness affecting
children, and infection in young adults and during pregnancy was
uncommon, estimated to occur in 6 per 100 000 pregnancies.2,3
However, as measles vaccine coverage increased in countries, the
chance of measles virus exposure in childhood decreased substan-
tially and the age at onset of disease shifted to include young adults
and women of reproductive age.4–6 During 2009–2010, measles
outbreaks in a number of African countries demonstrated this shift
in measles epidemiology, characterized by cases occurring among
older children and young adults.4 Diseases. This is an open access article under the CC BY-NC-ND license (http://
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population of 2.1 million.7 In 2014, Namibia had an HIV prevalence
among adults aged 15–49 years of 16.0%, one of the highest in the
world,8 and high compared with other countries in the Sub-
Saharan Africa region.9 Routine measles vaccination at 9 months of
age began in 1983, before independence from South Africa.10WHO
and United Nations Children’s Fund estimates of coverage among
12–23-month-olds with the ﬁrst dose of measles-containing
vaccine in Namibia decreased from 76% in 1989 to 58% in 2001,
ranged from 63% to 76% during 2002–2012, and increased to 83% in
2014.10 In addition to vaccination through routine immunization
services, periodic measles supplementary immunization activities
(SIAs) have been conducted every 3 years, starting in 1997,
following the WHO-recommended strategy for measles mortality
reduction, with reported administrative coverage of 90–104%.11,12
From August 2, 2009 through February 2, 2011, a large measles
outbreak occurred in Namibia, with 3256 laboratory-conﬁrmed or
epidemiologically linked cases.11,13 A distinguishing feature of this
outbreak was that 38% of reported cases occurred among adults
aged 15 years, including women of reproductive age. Measles
cases in pregnant women in Namibia during this outbreak resulted
in adverse maternal, fetal, and neonatal outcomes, including
neonatal and maternal death.14 In response to the outbreak,
outbreak response immunization (ORI) targeting children aged 6–
59 months, regardless of previous measles vaccination, was
conducted in seven districts in 2009–2010.13 ORI targeting all
persons aged 6 months was implemented in February 2010 in
Opuwo district, where the highest number of measles cases was
reported during the outbreak,13,15 and ORI targeting persons aged
6 months to 35 years was conducted in three districts during May–
June 2010.
To estimate measles population immunity in Namibian
pregnant women before and late in the measles outbreak and to
examine factors associated with seroprevalence (including HIV
status), stored serum samples from the 2008 and 2010 national
HIV surveys among pregnant women aged 15–44 years old were
tested. It was reasoned that assessing the level of measles
immunity in pregnant women in Namibia would provide
substantial new knowledge towards understanding the level of
susceptibility and the potential burden of disease in this
population and would help guide immunization program activities
needed in Namibia to achieve measles elimination.
2. Methods
2.1. National HIV Sentinel Survey
In 2008 and 2010, the Namibia Ministry of Health and Social
Services (MoHSS) conducted a nationwide sentinel survey to
estimate HIV prevalence in pregnant women aged 15–49 years.
The survey was designed in accordance with the WHO standard-
ized methodology for HIV prevalence surveys using convenient
consecutive sampling of women attending antenatal clinic (ANC)
service sites selected based on geographic representation from all
regions and health districts, urban and rural clinics, areas with
different population densities and sizes, and women of different
socioeconomic status.16,17 All pregnant women aged 15–49 years
were included in the survey if they attended an ANC for the ﬁrst
time during their current pregnancy, were not referred from
another health facility, and agreed to a routine blood draw.
The 2008 survey enrolled 8174 women from all 34 districts,
35 main hospital sites, and 89 satellite health centers and clinics;
8024 (98.2%) enrollees had specimens collected during March 17 to
July 31, 2008.17 The 2010 survey enrolled 7983 pregnant women
from all 34 districts, 35 main hospitals, and 93 satellite health
centers and clinics; 7888 (98.8%) enrollees had specimenscollected during March 22 to September 6, 2010.16 Most conﬁrmed
measles cases in the 2009–2011 outbreak occurred before the start
of the 2010 survey (2519 of the 3256 conﬁrmed cases, or 77%).13 In
both surveys, unlinked, de-identiﬁed specimens were tested for
HIV antibodies; all de-identiﬁed data ﬁelds were retained
electronically (unique identiﬁcation, district abbreviation and site
number, facility type, date of ANC visit, woman’s age, gravidity,
town of residence, antiretroviral therapy participation, and
counseling for prevention of maternal to child transmission).
Specimens were stored at 4–8 8C at the Namibia Institute of
Pathology (NIP) in Windhoek.
2.2. Laboratory testing
Laboratory testing to detect measles-speciﬁc immunoglobulin
G (IgG) antibody was performed at the NIP in 2012, using an
enzyme immunoassay (EIA) (Enzygnost, Siemens, Germany); the
manufacturer’s recommended standard operating procedures
were followed. The manufacturer assigns specimens with cor-
rected optical density (OD) values >0.2 as positive, specimens with
values of 0.1–0.2 as equivocal, and specimens with values <0.1 as
negative. However, these classiﬁcations are designed for testing
individuals and not population studies.18 Using the quantitative
evaluation recommended by the manufacturer, sample assays in
the equivocal range resulted in titers ranging from 149 to 342 mIU/
ml, which are higher than the accepted protective antibody
concentration of 120 mIU/ml.19,20 As a result, specimens with OD
0.1 were considered to be positive, which is consistent with
previous studies suggesting the antibody levels in the equivocal
range are protective against measles.18,21,22 Positive, equivocal,
and negative specimens are reported separately, but analyses were
conducted using a combined grouping of positives and equivocals
compared to negative specimens. Specimens that tested equivocal
were retested as per the manufacturer’s instructions, and if the
result was conﬁrmed, samples were classiﬁed as equivocal,
otherwise as positive or negative.
To monitor the performance of the EIA assay, an in-house
positive control for measles IgG was included on every EIA plate in
addition to the controls supplied by the manufacturer. A 5%
random sample of specimens was tested at the Centers for Disease
Control and Prevention (CDC) in Atlanta, USA, for quality
assurance; testing was found to be highly concordant with that
at NIP (data not shown).
2.3. Sample size calculations
To estimate measles antibody seroprevalence within each 5-year
age group with a desired precision of 5%, it was determined to be
necessary to test 428 specimens in each age group, assuming a
seroprevalence of 50%, probability of achieving the desired precision of
0.95, and 10% loss due to specimens not found or inadequate for testing.
The number of specimens in the 45–49 years age stratum was too few
to result in meaningful estimates and these samples were excluded.
The number of specimens in the 40–44 years age stratum was fewer
than the target, so all specimens were sampled. To control for the
distribution of HIV-infected women within each age group, the target
sample size was allocated to the HIV-positive and HIV-negative groups
based on the observed distribution in the ANC sentinel survey.16,17
2.4. Statistical analyses
A seroprevalence estimate and 95% conﬁdence interval (CI)
using the Wilson score method were calculated for each 5-year age
group in each analysis year and within the following sub-
populations: urban/rural setting, HIV status, gravidity, facility
type (hospital, health center, or clinic), and health district. For each
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seropositivity (positives and equivocals vs. negatives) while
controlling for age group, urban/rural setting, HIV status, gravidity,
and facility type. For the comparison of measles seroprevalence
before and late in the outbreak in 2008 and 2010, the analysis was
restricted to those birth cohorts present in both 2008 and 2010,
and adjusted for the age they would have been in 2008, calculating
an adjusted odds ratio (OR) for difference by year. All analyses
included sampling weights, which were calculated based on the
probability of selection of a specimen within each of the 12 age and
HIV status strata from all specimens collected, and adjusted for
non-response (i.e., specimens unavailable or inadequate for
testing) in each of the strata by the propensity cell adjustment
method. These weights were then scaled to the total sample size:
(weight/sum of weights)  total sample. A large percentage of
specimens were unavailable or inadequate for testing. However,
demographic information was available for all women sampled, so
multiple imputation was conducted using chained equations to
impute seropositivity; the imputed results were compared with
estimates based on available data. As the imputed estimates were
not substantially different from the estimates based on the
complete non-missing data, only the laboratory results from
complete specimens tested are reported. The multiple imputations
were done using the mice package in R statistical software version
3.1.2. Other data were analyzed using SAS version 9.3 (SAS
Institute, Cary, NC, USA). Comparisons of seroprevalence among
groups and between analysis years were calculated using the
Mantel–Haenszel and Chi-square tests on the weighted data. This
study received ethical approval from the CDC and the Namibia
MoHSS.Table 1
Target and observed sample sizes by age group and HIV status, among pregnant wom
Age group, years HIV status Total
specimens
Target
sample size
15–19 Positive 77 25 
Negative 1428 457 
20–24 Positive 339 68 
Negative 2085 414 
25–29 Positive 445 115 
Negative 1428 367 
30–34 Positive 327 132 
Negative 877 350 
35–39 Positive 193 127 
Negative 548 335 
40–44 Positive 44 44 
Negative 204 204 
All ages Both 7995 2638 
Table 2
Target and observed sample sizes by age group and HIV status, among pregnant wom
Age group, years HIV status Total
specimens
Target
sample size
15–19 Positive 86 32 
Negative 1264 450 
20–24 Positive 282 60 
Negative 1994 422 
25–29 Positive 410 110 
Negative 1398 372 
30–34 Positive 373 145 
Negative 871 337 
35–39 Positive 222 144 
Negative 523 338 
40–44 Positive 71 71 
Negative 211 211 
All ages Both 7705 2692 3. Results
Of the 2638 specimens collected in 2008 that were selected for
inclusion in the study, 1708 (64.7%) were tested (Table 1); 443
(16.8%) were unavailable, 437 (16.6%) had insufﬁcient volume, one
(0.04%) was hemolyzed and could not be used for laboratory
testing, and 49 (1.9%) were missing the measles IgG laboratory
result. Of the 2692 specimens collected in 2010 that were selected
for inclusion in the study, 2040 (75.8%) were tested (Table 2); 389
(14%) were unavailable, 230 (8%) had insufﬁcient volume, 29 (1%)
were hemolyzed and could not be used for laboratory testing, and
four (0.1%) were missing the measles IgG laboratory result. No
substantial differences in the demographics of persons whose
specimens were not tested and those of persons whose specimens
were tested and included in the analysis was found, by age group,
urban/rural setting, or gravidity (data not shown). A larger
proportion of HIV-positive (74%) than HIV-negative (27%) speci-
mens collected in 2008 were unavailable for testing; this was likely
due to prior use of these specimens in antiretroviral resistance
studies. Of the specimens collected in 2010 that were available for
testing, no difference was observed in the proportion of HIV-
positive (24%) and HIV-negative (24%) specimens.
Overall measles seroprevalence (positives and equivocals) was
87% (95% CI 86–89%) in 2008 and 87% (95% CI 85–88%) in 2010
(Tables 3 and 4). Measles antibody seroprevalence increased with
increasing age group in both analysis years; in 2008, seropreva-
lence was 77% for 15–19-year-olds and 91–93% for 25-year-olds
(p < 0.001), and in 2010, seroprevalence was 77% for 15–19-year-
olds and 94% for 40–44-year-olds (p < 0.001). Seroprevalence
differed by gravidity in 2008 (p < 0.001) and 2010 (p < 0.001). Noen aged 15–44 years, from the 2008 HIV Sentinel Survey, Namibia
% of total
specimens sampled
Observed
sample size
% not tested
(target  observed/target)
32 4 84
32 332 27
20 17 75
20 306 26
26 35 70
26 271 26
40 40 70
40 245 30
66 42 67
61 254 24
100 9 80
100 153 25
33 1708 35
en aged 15–44 years, from the 2010 HIV Sentinel Survey, Namibia
% of total specimens
sampled
Observed
sample size
% not tested
(target  observed/target)
37 24 25
36 335 26
21 46 23
21 321 24
27 81 26
27 283 24
39 110 24
39 259 23
65 115 20
65 252 25
100 53 25
100 161 24
35 2040 24
Table 3
Measles seroprevalence among pregnant women aged 15–44 years, overall and by age group, HIV status, gravidity, and setting, from the 2008 HIV Sentinel Survey, Namibia
Unweighted
total, N
Weighted
% positive
95% CIa Weighted
% equivocal
95% CIa Weighted
% negative
95% CIa Weighted
% positive
and equivocalb
95% CIa p-Valuec
Overall 1708 76 74–78 11 10–12 13 11–14 87 86–89
Age group, years <0.001
15–19 336 61 56–66 16 12–20 23 19–28 77 72–81
20–24 323 74 70–78 13 10–16 13 10–16 87 84–90
25–29 306 80 76–84 11 9–15 8 6–12 91 88–94
30–34 285 86 81–90 6 4–10 8 5–12 92 88–95
35–39 266 90 84–94 3 1–7 7 4–12 93 88–96
40–44 162 89 78–95 2 0–10 9 4–20 91 80–96
HIV status 0.855
Positive 147 78 71–84 10 6–16 12 8–19 88 81–92
Negative 1561 76 74–78 11 10–13 13 11–14 87 86–89
Gravidity <0.001
1 509 66 63–70 15 12–18 19 16–22 81 78–84
2 349 80 76–84 10 8–13 10 7–13 90 87–93
3 264 76 71–81 12 9–17 11 8–16 89 84–92
4+ 519 88 84–91 5 3–7 7 5–10 93 90–95
Setting 0.509
Rural 758 77 74–80 11 9–13 12 10–15 88 85–90
Urban 950 76 73–79 11 9–13 13 11–16 87 84–89
CI, conﬁdence interval.
a Wilson score method.
b Equivocals treated as positive.
c Chi-square comparing negatives vs. the sum of positives and equivocals.
Table 4
Measles seroprevalence among pregnant women aged 15–44 years, overall and by age group, facility type, HIV status, gravidity, and setting, from the 2010 HIV Sentinel
Survey, Namibia
Unweighted
total, N
Weighted
% positive
95% CIa Weighted
% equivocal
95% CIa Weighted
% negative
95% CIa Weighted
% positive and
equivocalb
95% CIa p-Valuec
Overall 2041 74 72–76 13 12–15 13 12–15 87 85–88
Age group, years <0.001
15–19 358 56 51–62 21 17–26 23 18–27 77 73–81
20–24 368 71 68–75 13 11–16 16 13–19 85 81–87
25–29 364 77 73–81 13 10–16 10 8–13 90 87–92
30–34 369 80 75–84 11 8–15 9 6–12 91 88–94
35–39 367 88 82–91 6 3–10 6 4–11 93 89–96
40–44 215 91 82–95 4 1–11 6 2–13 94 87–98
Facility 0.362
Hospital 232 74 68–79 14 10–18 13 9–17 87 83–91
Health center 301 72 67–77 12 9–17 16 12–20 84 80–88
Clinic 1508 74 72–76 13 12–15 13 11–14 87 86–89
HIV status 0.478
Positive 430 76 71–80 12 9–16 12 9–16 88 84–91
Negative 1611 73 71–75 13 12–15 13 12–15 87 85–88
Gravidity <0.001
1 566 66 62–69 15 13–18 19 17–23 81 77–83
2 396 75 71–79 13 10–16 12 9–15 88 85–91
3 349 75 70–79 15 12–20 10 7–14 90 87–93
4+ 730 82 79–86 10 7–12 8 6–11 92 89–94
Setting 0.060
Rural 1130 72 70–75 13 12–16 14 12–17 86 86–90
Urban 911 76 73–78 13 11–15 12 10–14 88 83–88
CI, conﬁdence interval.
a Wilson score method.
b Equivocals treated as positive.
c Chi-square comparing negatives vs. the sum of positives and equivocals.
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facility type, HIV status, or urban/rural residence in 2008 and
2010. When stratiﬁed by age group, no signiﬁcant differences were
observed in measles seroprevalence by HIV status (Table 5) or by
gravidity (data not shown). A comparison of measles seropreva-
lence in 2008 versus 2010 found no signiﬁcant difference between
years (OR 1.04, p = 0.711).Table 6 shows the results from the multivariable models for
2008 and 2010, calculating the odds of measles seropositivity
while adjusting for age group, HIV status, facility type, gravidity,
and urban/rural setting. In 2008 and 2010, women 20 years of
age and older had higher odds of seropositivity compared
with women 15–19 years of age (2008, p = 0.002; 2010,
p = 0.010).
Table 5
Measles seroprevalence among pregnant women aged 15–44 years, by age and HIV status, from the 2008 and 2010 HIV sentinel surveys, Namibia
Age group, years HIV status 2008 2010
Unweighted
total, N
Weighted
% positive and
equivocal (95% CIa)
Mantel–Haenszel
p-Value
Unweighted
total, N
Weighted
% positive and
equivocal (95% CIa)
Mantel–Haenszel
p-Value
15–19 Negative 332 77 (73–82) 334 78 (73–82)
Positive 4 25 (5–70) 24 67 (46–82)
20–24 Negative 306 87 (84–90) 322 85 (82–88)
Positive 17 88 (72–96) 46 83 (71–90)
25–29 Negative 271 92 (88–94) 283 90 (87–93)
Positive 35 91 (80–97) 81 89 (82–94)
30–34 Negative 245 93 (88–96) 259 91 (86–94)
Positive 40 88 (72–95) 110 92 (85–96)
35–39 Negative 254 93 (88–96) 252 93 (88–96)
Positive 42 90 (71–97) 115 94 (85–98)
40–44 Negative 153 90 (79–96) 161 96 (87–99)
Positive 9 100 (44–100) 54 91 (70–98)
0.279 0.370
CI, conﬁdence interval.
a Wilson score method.
Table 6
Logistic regression calculating the odds of measles seropositivity among pregnant
women aged 15–44 years from the 2008 and 2010 HIV sentinel surveys, Namibiaa
2008 2010
OR 95% CI p-Value OR 95% CI p-Value
Age group, years 0.002 0.010
15–19 Ref. Ref.
20–24 1.80 1.23–2.63 0.002 1.38 0.96–1.98 0.079
25–29 2.77 1.67–4.59 <0.001 2.09 1.31–3.35 0.002
30–34 2.76 1.43–5.32 0.002 2.92 1.30–4.05 0.004
35–39 3.02 1.36–6.73 0.007 3.21 1.54–6.70 0.002
40–44 2.12 0.72–6.28 0.172 3.72 1.22–11.35 0.021
Facilityb 0.456
Hospital Ref.
Health center 0.80 0.48–1.32 0.373
Clinic 0.99 0.65–1.52 0.974
HIV status 0.307 0.286
Positive Ref. Ref.
Negative 1.34 0.76–2.36 0.307 1.22 0.85–1.74 0.286
Gravidity 0.063 0.258
1 Ref.
2 1.64 1.10–2.46 0.016 1.39 0.96–2.00 0.080
3 1.11 0.67–1.84 0.680 1.42 0.89–2.27 0.142
4+ 1.62 0.89–2.94 0.114 1.48 0.88–2.49 0.139
Setting 0.387 0.067
Rural Ref. Ref.
Urban 0.88 0.66–1.18 0.387 1.28 0.98–1.68 0.067
OR, odds ratio; CI, conﬁdence interval.
a Seropositive included both seropositive and equivocal.
b Data for facility type were not available in 2008.
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district; in 2008, seroprevalence ranged from 57% to 98%, and in
2010, seroprevalence ranged from 69% to 98%.
4. Discussion
This is the ﬁrst study of measles antibody seroprevalence in
Namibia. Because 13% of pregnant women and almost one in four
15–19-year-old pregnant women remained measles-susceptible
late in the outbreak in 2010, this study highlights a population of
women and their offspring at risk of measles and its complications.
As these women age and new birth cohorts are added to the
population, if SIAs do not target these young adults, overall
population measles susceptibility might increase from current
levels. Conducting periodic seroprevalence surveys in areas at high
risk of outbreaks could be valuable for identifying geographic areas
and sub-populations with low measles immunity. An indication ofresults from these surveys, along with vaccination coverage data
and case-based surveillance data, provide evidence for guiding
age-speciﬁc vaccine introduction strategies as well as determining
target age groups for SIAs. The ﬁndings of this study, together with
other data sources such as surveillance data, should help guide ORI
and SIA planning, including expanding target age groups beyond
children when indicated, to reach the 93–95% population
immunity needed to prevent measles outbreaks.23 Theoretical
disease modeling suggests achieving 6% to 8% measles suscepti-
bility in all age groups will likely prevent measles outbreaks.
However, heterogeneity of susceptibility exists, and higher levels
of measles susceptibility may occur in infants and preschool aged
children; in these settings, it may be necessary to achieve a
relatively lower level of measles susceptibility in age groups
known to have the highest contact and virus transmission rates,
particularly school-aged children and young adults.24
The occurrence of large measles outbreaks might have a
signiﬁcant boosting effect on overall population immunity because
large numbers of measles-susceptible persons acquire immunity
naturally following infection during the outbreak. However, in the
present study, measles seroprevalence among adult pregnant
women remained unchanged late in the measles outbreak (2010)
compared with before the outbreak (2008), suggesting the
outbreak did not affect population immunity substantially.
No effect of HIV status on measles seroprevalence was found.
Past studies have shown a decreased serological response to
measles vaccination among HIV-infected adults, waning immunity
following vaccination in HIV-positive infants and children, and
lower protective immunity to measles among infants born to HIV-
infected mothers.25–28 Although HIV infection is associated with
lower vaccine effectiveness29 and an increased risk of measles
outbreaks,30 the contribution of the HIV pandemic to measles
control and elimination in Sub-Saharan Africa appears to be
minimal.31–33 The present ﬁndings mirror those of a Kenyan
measles seroprevalence study in HIV-positive and negative adults,
which also found no differences between these two populations.34
It is likely that an association between HIV status and measles
seroprevalence was not found because the study population
received measles vaccination as children and acquired HIV as
adults, with no loss of protective immunity.34 Because of the severe
course of measles in patients with advanced HIV infection, the
WHO recommends that, in areas with a high incidence of both HIV
and measles, the ﬁrst dose of measles-containing vaccine be
administered as early as 6 months of age, followed by two
additional doses of measles vaccine according to the national
Table 7
Measles seroprevalence among pregnant women aged 15–44 years, by health district, from the 2008 and 2010 HIV sentinel surveys, Namibia
District 2008 2010
Unweighted, N Weighted
% negative (95% CIa)
Weighted
% positive and
equivocal (95% CIa)
Unweighted, N Weighted %
negative (95% CIa)
Weighted
% positive and
equivocal (95% CIa)
Andara 42 36 (23–50) 64 (49–77) 53 14 (7–26) 86 (74–93)
Aranos 24 12 (4–29) 88 (71–96) 16 8 (2–27) 92 (73–98)
Eenhana 77 11 (6–20) 89 (80–94) 67 22 (14–34) 77 (66–86)
Engela 70 6 (3–14) 94 (86–97) 72 17 (10–27) 83 (73–90)
Gobabis 35 7 (2–20) 93 (80–98) 66 6 (3–15) 94 (85–97)
Grootfontein 59 8 (3–18) 92 (82–97) 50 2 (0–10) 98 (91–100)
Oshakati 82 2 (0–7) 98 (93–100) 79 17 (10–26) 83 (74–90)
Karasburg 33 6 (2–18) 94 (82–98) 37 4 (1–16) 96 (84–99)
Katutura 68 4 (1–11) 96 (89–99) 76 5 (2–12) 95 (88–98)
Keetmanshoop 5b 46 14 (6–26) 86 (74–93)
Khorixas 26 30 (15–49) 74 (51–85) 41 10 (3–24) 90 (76–97)
Katima Mulilo 76 19 (12–29) 81 (71–88) 91 16 (10–25) 84 (75–90)
Luderitz 27 9 (3–26) 91 (74–97) 74 6 (2–13) 94 (87–98)
Mariental 27 6 (2–22) 94 (79–98) 41 4 (1–14) 96 (86–99)
Nankudu 56 12 (6–22) 88 (78–94) 36 14 (6–28) 86 (72–94)
Nyangana 28 19 (9–37) 81 (63–91) 75 13 (7–22) 87 (78–93)
Okahao 74 11 (6–21) 89 (79–94) 103 14 (8–23) 86 (77–92)
Okahandja 84 9 (5–17) 91 (83–95) 54 18 (10–30) 82 (69–90)
Okakarara 41 10 (4–24) 90 (76–96) 48 30 (19–44) 70 (57–81)
Okongo 38 13 (5–28) 87 (72–95) 88 13 (7–23) 87 (77–93)
Omaruru 40 27 (16–42) 73 (58–84) 52 11 (5–24) 89 (76–95)
Onandjokwe 81 15 (9–25) 85 (75–91) 85 23 (16–34) 77 (66–85)
Opuwo 38 13 (6–26) 87 (74–94) 17 12 (3–38) 88 (62–97)
Oshikuku 49 3 (1–12) 97 (88–99) 70 6 (3–14) 94 (86–97)
Otjiwarongo 34 7 (2–21) 93 (79–98) 62 10 (4–20) 90 (80–96)
Outjo 42 15 (8–28) 85 (72–92) 60 30 (20–43) 69 (57–80)
Outapi 76 6 (2–14) 94 (86–98) 50 6 (2–16) 94 (84–98)
Rehoboth 52 13 (6–25) 87 (75–94) 26 10 (3–27) 90 (73–97)
Rundu 42 26 (15–40) 75 (60–85) 67 10 (5–19) 90 (81–95)
Swakopmund 50 16 (8–28) 84 (72–92) 56 5 (2–14) 95 (86–98)
Tsandi 48 27 (16–41) 73 (59–84) 87 14 (8–23) 86 (77–92)
Tsumeb 83 12 (6–20) 88 (80–94) 72 16 (9–26) 84 (74–91)
Usakos 26 25 (12–44) 75 (56–88) 22 16 (6–36) 84 (64–93)
Walvis Bay 36 21 (11–37) 79 (63–89) 71 16 (10–27) 84 (73–90)
Windhoek Central Hospital 39 11 (5–24) 89 (75–95) 31 13 (5–28) 87 (72–95)
CI, conﬁdence interval.
a Wilson score method.
b Number too small to calculate meaningful statistics.
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istered routinely to potentially susceptible, asymptomatic HIV-
positive children and adults, and considered for those with
symptomatic HIV infection if not severely immunosuppressed.23
These ﬁndings should be considered in light of certain
limitations. First, only pregnant women aged 15–44 years were
examined in this study, and the ANC survey was not a random
cross-section of the population of pregnant women. Therefore, the
results might not be generalizable to all pregnant women or to
other age groups and populations in Namibia. When feasible,
prospective, population-based surveys could be considered to
increase the generalizability of results and allow for the collection
of additional information on variables of interest, such as
immunization status; however, these studies are time- and
resource-intensive, and utilizing specimens already collected
and stored might allow for studies that would not otherwise be
possible. Second, two cohorts of pregnant women who had
specimens collected in 2008 and 2010 were tested, thus the same
women might have been included by chance; however, because
the specimens were de-identiﬁed and unlinked, it could not be
determined whether this occurred. This limits inferences regarding
differences in measles seropositivity between the two populations.
Third, measles immunity was measured before the end of the
outbreak; immunity might have been higher if immunity had been
measured after the outbreak. However, the second survey wasconducted after 77% of measles cases had occurred in the outbreak,
and it is believed that the additional cases that occurred during and
after the 2010 survey would not have affected these ﬁndings
substantially. Fourth, fewer HIV-positive specimens were available
for testing compared with HIV-negative samples for the 2008 study
year, and this could have biased the results. However, this
difference in specimens was not seen in 2010, and similar ﬁndings
were observed in both analysis years, making this bias less likely.
The cutoffs for the EIAs used to determine protective levels of
antibody have varied considerably in measles seroprevalence
studies depending on the methodology used, although there is a
growing movement to standardize testing and report comparable
outcomes. Persons with antibody titers in the equivocal and
sometimes negative qualitative ranges, when retested by plaque
reduction neutralization (PRN) test, have been found to have
protective antibodies against measles.18,21 Additionally, persons
who are vaccinated may have lower titers than those who are
infected with wild-type virus.18,21,35 This may explain the
differences by age group seen in the present study, with the
highest percentage of equivocals in the youngest age groups (16–
21% in 15–19-year-olds), as these youngest cohorts would have
had the opportunity to receive measles vaccination through the
routine immunization program which began in 1983. Unfortunate-
ly, this cannot be conﬁrmed because the participants’ vaccination
histories were not available. Nonetheless, as seroprevalence
C.V. Cardemil et al. / International Journal of Infectious Diseases 49 (2016) 189–195 195studies expand in settings where adults might have been
vaccinated or exposed to wild-type virus but documentation of
vaccination is not readily available, deﬁning the appropriate cutoff
for protection is critical for guiding programs and standardizing
reporting across different settings.
In Namibia, the results from this study together with other data,
including from surveillance showing a high age-speciﬁc incidence
of measles in persons up to 39 years of age, is evidence of immunity
gaps in adults beyond the usual SIA target groups. Additionally,
since this study was conducted, measles outbreaks have continued
in Namibia in 2013–2014, and cases continue to occur in older age
groups.36 Based on these recurrent outbreaks in adults and lower
than expected seroprevalence, the MoHSS is considering imple-
menting a nationwide SIA with measles–rubella vaccine among
persons aged 9 months to 39 years, a target population of
1.8 million persons in 2016.37 If high coverage can be achieved and
sustained in both routine immunization services and SIAs, Namibia
will be one step closer to achieving the goal of measles elimination.
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